JP7411631B2 - インターロイキン-1活性の阻害剤としてのスルホニル尿素化合物 - Google Patents

インターロイキン-1活性の阻害剤としてのスルホニル尿素化合物 Download PDF

Info

Publication number
JP7411631B2
JP7411631B2 JP2021502998A JP2021502998A JP7411631B2 JP 7411631 B2 JP7411631 B2 JP 7411631B2 JP 2021502998 A JP2021502998 A JP 2021502998A JP 2021502998 A JP2021502998 A JP 2021502998A JP 7411631 B2 JP7411631 B2 JP 7411631B2
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
disease
dihydro
pyrazolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021502998A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021530536A5 (cg-RX-API-DMAC7.html
JP2021530536A (ja
Inventor
スタッフォード,ジェフリー・エー
ヴィール,ジェームズ・エム
トルゾス,リニー・リン
マクブライド,クリストファー
パスター,リチャード・エム
スタベン,スティーヴン・トーマス
スティバラ,クレイグ
ヴォルグラフ,マシュー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2021530536A publication Critical patent/JP2021530536A/ja
Publication of JP2021530536A5 publication Critical patent/JP2021530536A5/ja
Application granted granted Critical
Publication of JP7411631B2 publication Critical patent/JP7411631B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2021502998A 2018-07-20 2019-07-19 インターロイキン-1活性の阻害剤としてのスルホニル尿素化合物 Active JP7411631B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862701358P 2018-07-20 2018-07-20
US62/701,358 2018-07-20
PCT/US2019/042703 WO2020018970A1 (en) 2018-07-20 2019-07-19 Sulfonylurea compounds as inhibitors of interleukin-1 activity

Publications (3)

Publication Number Publication Date
JP2021530536A JP2021530536A (ja) 2021-11-11
JP2021530536A5 JP2021530536A5 (cg-RX-API-DMAC7.html) 2022-07-25
JP7411631B2 true JP7411631B2 (ja) 2024-01-11

Family

ID=67515207

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021502998A Active JP7411631B2 (ja) 2018-07-20 2019-07-19 インターロイキン-1活性の阻害剤としてのスルホニル尿素化合物

Country Status (20)

Country Link
US (1) US11560391B2 (cg-RX-API-DMAC7.html)
EP (1) EP3823726A1 (cg-RX-API-DMAC7.html)
JP (1) JP7411631B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210034588A (cg-RX-API-DMAC7.html)
CN (1) CN112437683A (cg-RX-API-DMAC7.html)
AR (1) AR117617A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019305095A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021001012A2 (cg-RX-API-DMAC7.html)
CA (1) CA3104199A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021000152A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021000817A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210024A (cg-RX-API-DMAC7.html)
IL (1) IL280139A (cg-RX-API-DMAC7.html)
MA (1) MA53170A (cg-RX-API-DMAC7.html)
MX (1) MX2021000660A (cg-RX-API-DMAC7.html)
PE (1) PE20211049A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020552155A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202012159TA (cg-RX-API-DMAC7.html)
TW (1) TW202019937A (cg-RX-API-DMAC7.html)
WO (1) WO2020018970A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA126675C2 (uk) 2017-01-23 2023-01-11 Дженентек, Інк. Хімічні сполуки як інгібітори активності інтерлейкіну-1
WO2019034693A1 (en) 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
TW201910317A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
MX2020001776A (es) 2017-08-15 2020-03-24 Inflazome Ltd Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
WO2019092171A1 (en) 2017-11-09 2019-05-16 Inflazome Limited Novel sulfonamide carboxamide compounds
CN111315733A (zh) 2017-11-09 2020-06-19 英夫拉索姆有限公司 新颖磺酰胺甲酰胺化合物
WO2019166619A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
MA53172A (fr) 2018-07-20 2021-05-26 Hoffmann La Roche Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1
CN114008030A (zh) 2019-06-21 2022-02-01 Ac免疫有限公司 用作nlrp3调节剂的稠合的1,2-噻唑和1,2-噻嗪
CA3158123A1 (en) * 2019-11-12 2021-05-20 Yonggang Wei Amide derivative and preparation method therefore and use thereof in medicine
BR112022014480A2 (pt) 2020-01-22 2022-09-13 Hoffmann La Roche Compostos, composições farmacêutica, método para tratar um distúrbio em um paciente, usos de um composto e de uma composição farmacêutica e kit
US12624010B2 (en) 2020-06-19 2026-05-12 Ac Immune Sa Dihydrooxazole and thiourea derivatives modulating the NLRP3 inflammasome pathway
JP2025502732A (ja) 2021-12-22 2025-01-28 エーシー・イミューン・エス・アー ジヒドロオキサゾール誘導体化合物
CA3252822A1 (en) 2022-02-21 2023-08-24 Viva Star Biosciences (Suzhou) Co., Ltd. NOVEL BICYCLIC SUBSTITUTED SULFONYLUREA COMPOUNDS AS INTERLEUKIN-1 ACTIVITY INHIBITORS
JP2025524640A (ja) 2022-07-14 2025-07-30 エーシー・イミューン・エス・アー Nlrp3インフラマソーム経路の調節剤としてのピロロトリアジン及びイミダゾトリアジン誘導体
WO2024023266A1 (en) 2022-07-28 2024-02-01 Ac Immune Sa Novel compounds
TW202545527A (zh) 2024-01-16 2025-12-01 英商諾得瑟拉公司 Nlrp3及glp-1a組合療法
CN122555708A (zh) 2024-01-17 2026-08-11 Ac免疫有限公司 用作nlrp3炎症小体通路抑制剂的咪唑并[1,2-d][1,2,4]三嗪衍生物
CN122555707A (zh) 2024-01-17 2026-08-11 Ac免疫有限公司 用作nlrp3炎症小体通路抑制剂的咪唑并[1,2-d][1,2,4]三嗪衍生物
WO2025163069A1 (en) 2024-01-31 2025-08-07 Ac Immune Sa Novel compounds
WO2026132518A1 (en) 2024-12-20 2026-06-25 Ac Immune Sa Heterocyclic compounds modulating the nlrp3 inflammasome pathway

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000511200A (ja) 1997-01-29 2000-08-29 ファイザー・インク スルホニルウレア誘導体、およびインターロイキン−1の活性を制御する上でのスルホニルウレア誘導体の使用
WO2017140778A1 (en) 2016-02-16 2017-08-24 The University Of Queensland Sulfonylureas and related compounds and use of same
JP2018510207A (ja) 2015-02-16 2018-04-12 ザ ユニバーシティ オブ クィーンズランド スルホニル尿素及び関連化合物並びにその使用
JP2020505381A (ja) 2017-01-23 2020-02-20 ジェネンテック, インコーポレイテッド インターロイキン−1活性の阻害剤としての化学化合物

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216026A (en) 1990-07-17 1993-06-01 Eli Lilly And Company Antitumor compositions and methods of treatment
BR0014003A (pt) 1999-09-14 2002-05-21 Pfizer Prod Inc Tratamento de combinação com compostos de diaril sufonil uréia e il-1ra
AU2002341321A1 (en) 2001-11-30 2003-06-10 Pfizer Products Inc. Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation
CA2789665C (en) * 2010-02-22 2020-06-16 Askat Inc. Use of ep4 receptor antagonists in the treatment of il-23 mediated diseases
TW201311693A (zh) 2011-09-02 2013-03-16 Kyowa Hakko Kirin Co Ltd 化學激活激素受體活性調節劑
MA44729A (fr) 2016-04-18 2021-05-12 Novartis Ag Composés et compositions pour traiter des états associés à une activité de nlrp
US11447460B2 (en) 2016-04-18 2022-09-20 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
US11840543B2 (en) 2017-05-24 2023-12-12 The University Of Queensland Compounds and uses
EP3649112A1 (en) 2017-07-07 2020-05-13 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
CN110914256A (zh) 2017-07-07 2020-03-24 英夫拉索姆有限公司 新颖磺酰胺羧酰胺化合物
MX2020001776A (es) 2017-08-15 2020-03-24 Inflazome Ltd Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
WO2019034693A1 (en) 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
EP3668862A1 (en) 2017-08-15 2020-06-24 Inflazome Limited Novel sulfonamide carboxamide compounds
WO2019034697A1 (en) 2017-08-15 2019-02-21 Inflazome Limited NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS
TW201910317A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
AU2018317800A1 (en) 2017-08-15 2020-02-13 Inflazome Limited Novel sulfonamide carboxamide compounds
TW201910314A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
WO2019043610A1 (en) 2017-08-31 2019-03-07 Cadila Healthcare Limited NEW SUBSTITUTED SULFONYLUREA DERIVATIVES
WO2019092171A1 (en) 2017-11-09 2019-05-16 Inflazome Limited Novel sulfonamide carboxamide compounds
WO2019092172A1 (en) 2017-11-09 2019-05-16 Inflazome Limited Novel sulfonamide carboxamide compounds
CN111315733A (zh) 2017-11-09 2020-06-19 英夫拉索姆有限公司 新颖磺酰胺甲酰胺化合物
GB201721185D0 (en) 2017-12-18 2018-01-31 Nodthera Ltd Sulphonyl urea derivatives
GB201803393D0 (en) 2018-03-02 2018-04-18 Inflazome Ltd Novel compounds
GB201803394D0 (en) 2018-03-02 2018-04-18 Inflazome Ltd Novel compounds
WO2019166619A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
GB201806578D0 (en) 2018-04-23 2018-06-06 Inflazome Ltd Novel compound
JP2021529780A (ja) 2018-07-03 2021-11-04 ノバルティス アーゲー Nlrp3アンタゴニストを使用するtnf阻害剤に対して抵抗性の対象のための治療の方法又は治療を選択する方法
JP2021529187A (ja) 2018-07-03 2021-10-28 ノバルティス アーゲー Nlrpモジュレータ
MA53172A (fr) 2018-07-20 2021-05-26 Hoffmann La Roche Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1
AR117951A1 (es) 2018-07-20 2021-09-08 Gruenenthal Gmbh Derivados de triazolquinoxalina adicionalmente sustituidos
SG11202101480XA (en) 2018-08-15 2021-03-30 Inflazome Ltd Novel sulfonamideurea compounds
GB201902327D0 (en) 2019-02-20 2019-04-03 Inflazome Ltd Novel compounds
GB201817038D0 (en) 2018-10-19 2018-12-05 Inflazome Ltd Novel processes
US20230011652A1 (en) 2018-10-24 2023-01-12 Novartis Ag Compounds and compositions for treating conditions associated with nlrp activity
GB201819083D0 (en) 2018-11-23 2019-01-09 Inflazome Ltd Novel compounds
US20220227707A1 (en) 2019-01-22 2022-07-21 Novartis Ag Compounds and compositions for treating conditions associated with nlrp activity
WO2021002887A1 (en) 2019-07-02 2021-01-07 Novartis Inflammasome Research, Inc. Gut-targeted nlrp3 antagonists and their use in therapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000511200A (ja) 1997-01-29 2000-08-29 ファイザー・インク スルホニルウレア誘導体、およびインターロイキン−1の活性を制御する上でのスルホニルウレア誘導体の使用
JP2018510207A (ja) 2015-02-16 2018-04-12 ザ ユニバーシティ オブ クィーンズランド スルホニル尿素及び関連化合物並びにその使用
WO2017140778A1 (en) 2016-02-16 2017-08-24 The University Of Queensland Sulfonylureas and related compounds and use of same
JP2020505381A (ja) 2017-01-23 2020-02-20 ジェネンテック, インコーポレイテッド インターロイキン−1活性の阻害剤としての化学化合物

Also Published As

Publication number Publication date
IL280139A (en) 2021-03-01
EP3823726A1 (en) 2021-05-26
SG11202012159TA (en) 2021-01-28
CR20210024A (es) 2021-02-22
CA3104199A1 (en) 2020-01-23
BR112021001012A2 (pt) 2021-04-20
CO2021000817A2 (es) 2021-02-17
US20210261568A1 (en) 2021-08-26
KR20210034588A (ko) 2021-03-30
PE20211049A1 (es) 2021-06-04
AU2019305095A1 (en) 2020-12-17
US11560391B2 (en) 2023-01-24
TW202019937A (zh) 2020-06-01
PH12020552155A1 (en) 2021-07-05
CL2021000152A1 (es) 2021-07-09
AR117617A1 (es) 2021-08-18
JP2021530536A (ja) 2021-11-11
MX2021000660A (es) 2021-03-25
WO2020018970A1 (en) 2020-01-23
MA53170A (fr) 2021-05-26
CN112437683A (zh) 2021-03-02

Similar Documents

Publication Publication Date Title
US11560391B2 (en) Sulfonylurea compounds as inhibitors of interleukin-1 activity
TWI825134B (zh) 作為介白素-1活性之抑制劑之磺醯脒(sulfonimidamide)化合物
JP6924267B2 (ja) ピロロ[1,2−b]ピリダジン誘導体
TWI789401B (zh) 新穎化合物
JP6663857B2 (ja) ピラゾロピリジンおよびピラゾロピリミジン
CA2886263C (en) Heteroaryl inhibitors of pde4
US8545897B2 (en) Pyrrolopyridines as kinase inhibitors
JP2023055855A (ja) 新規なスルホンアミドカルボキサミド化合物
CN112888675A (zh) 新型磺酰脲化合物
JP2022502476A (ja) インドールahr阻害剤およびその使用
WO2018167468A1 (en) Chemical compounds
JP2023542205A (ja) 新規化合物
US11878965B2 (en) Inhibitors of peptidylarginine deiminases
TW201249825A (en) Novel compounds
HK40040939A (en) Sulfonylurea compounds as inhibitors of interleukin-1 activity
RU2820289C2 (ru) Соединения сульфонимидамида в качестве ингибиторов активности интерлейкина-1
HK40052548A (en) Novel sulfoneurea compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220714

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220714

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230627

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230629

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231128

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231225

R150 Certificate of patent or registration of utility model

Ref document number: 7411631

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150